Immunic, a late-stage biotech company focused on neurologic diseases, has appointed Jaa Roberson as Chief People Officer to lead global talent and organizational strategy. This move supports Immunic's goal to build a strong multiple sclerosis (MS) organization ahead of pivotal Phase 3 trial results expected by the end of 2026 and potential commercialization of its drug vidofludimus calcium. Roberson brings over 20 years of HR experience in biopharma and will help scale the company from research to a fully integrated commercial entity. The appointment aligns with Immunic's preparation for regulatory filings and expanding its MS-focused team.
Immunic's leadership change is noted here with Pluang's Health sector data for context. As of Oct 19, 2026 17:11 WIB, 69 of 150 Health-sector US stocks on Pluang rose, 45 fell. Notable movers include AMRX at USD 19.55 (+1.93%), RLAY at USD 16.59 (+1.90%), and ERAS at USD 13.63 (+1.79%).
The global clinical trial supplies market is projected to grow from $5.7 billion in 2025 to $10.7 billion by 2033, at an 8.4% CAGR. This growth is driven by increased R&D investments, rising chronic diseases, and the expansion of biologics, personali...
Starlink Mobile, launched by VEON Ltd. across Ukraine, Kazakhstan, and Bangladesh, has connected over 11 million users in less than a year. The service enables existing 4G phones to access satellite connectivity where terrestrial signals are unavaila...
Medallion Financial Corp. announced it will repurchase $15 million in trust preferred securities from BIMIZCI Fund LLC at 73.66% of face value, costing about $11.05 million plus accrued distributions. This deal includes a five-year standstill agreeme...
Belite Bio, a clinical-stage drug developer focused on retinal diseases, has been approved to move its stock listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, the highest tier on Nasdaq. This uplisting reflects the company's ...
Heineken N.V. has repurchased a total of 8,865,521 shares under the second tranche of its €1.5 billion share buyback program, spending €629.4 million as of October 16, 2026. This includes shares bought on the exchange and from Heineken Holding N.V. T...
